Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1560774 | 0.84 | ALDH1A1 (0.39) | TDP1ALDH1A1MAPK14NR4A2METAP1 | |
| SCHEMBL14764526 | 0.84 | BCHE (0.41) | TDP1ALDH1A1MAPK14NR4A2BCHE | |
| SCHEMBL15665253 | 0.79 | MAPK14 (0.39) | TDP1ALDH1A1MAPK14NR4A2KDM4E | |
| SCHEMBL4685260 | 0.79 | NPC1 (0.39) | TDP1ALDH1A1MAPK14NR4A2BCHE | |
| SCHEMBL15665766 | 0.79 | MAPK14 (0.39) | TDP1ALDH1A1MAPK14NR4A2KDM4E | |
| SCHEMBL362622 | 0.79 | KDM4E (0.65) | TDP1ALDH1A1MAPK14METAP1KDM4E | |
| SCHEMBL14828909 | 0.79 | GOT1 (0.40) | TDP1ALDH1A1MAPK14NR4A2KDM4E | |
| SCHEMBL13344056 | 0.76 | ALDH1A1 (0.48) | TDP1ALDH1A1MAPK14METAP1KDM4E | |
| SCHEMBL28915934 | 0.76 | MAPT (0.55) | TDP1ALDH1A1MAPK14KDM4EBCHE | |
| Phenazine SCHEMBL19970688 | 0.76 | MAPT (0.55) | TDP1ALDH1A1MAPK14KDM4EBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210143337-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND DISPLAY DEVICE | SK MATERIALS CO., LTD. (KR) | 2021-05-13 | — | — | US | disclosed |
| EP-3461825-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2019-04-03 | — | — | EP | disclosed |
| EP-2760865-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2018-07-11 | — | — | EP | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-9586959-B2 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-7276507-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-7276507-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1660461-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021513-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | CCL2, CCL11, CCR2 | TDP1 3693/4885ALDH1A1 2310/4885MAPK14 922/4885 |
| US-20210143337-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND DISPLAY DEVICE | L1CAM, EML4, OCIAD2 | TDP1 3129/4885ALDH1A1 184/4885MAPK14 3138/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | TDP1 3457/4885ALDH1A1 1308/4885MAPK14 1612/4885 |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | TDP1 414/4885ALDH1A1 1192/4885MAPK14 99/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | TDP1 4238/4885ALDH1A1 2497/4885MAPK14 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.